Cancer immunotherapy with immune checkpoint inhibitors (icis): potential, mechanisms of resistance, and strategies for reinvigorating t cell responsiveness when resistance is acquired

HIGHLIGHTS

• who: Hany E. Marei from the Department of Cytology and Histology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, Egypt and Bioethics, Universitu00e0 Cattolica del Sacro Cuore, Rome, Italy have published the research: Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired, in the Journal: (JOURNAL) of May/16,/2019
• how: Recurrent GBM patients received either nivolumab or bevacizumab and the results showed that bevacizumab had a longer PFS of 3.5 months compared to nivolumab and no difference in OS .
•  

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.